This page was last updated on 21 March 2018

Click here to 
Print this page

Biography finder

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

 

 

Index of first names

Simon Douglas

 

 

 

 

 

Simon DouglasSimon Douglas is Chairman of Lab901. With over 20 years experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions, he was previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation in 2004.

 

Currently Simon is a non-executive director of the antibody-based therapeutics Company Fusion Antibodies, where he was previously the CEO, and also the Chief Executive of the diagnostic company Xynostics Ltd.

 

 

 

 

Any contributions will be gratefully accepted

 

 

Errors and Omissions

The Forum

What's new?

We are looking for your help to improve the accuracy of The Douglas Archives.

If you spot errors, or omissions, then please do let us know

Contributions

Many articles could benefit from re-writing. Can you help?


 

If you have met a brick wall with your research, then posting a notice in the Douglas Archives Forum may be the answer. Or, it may help you find the answer!

You may also be able to help others answer their queries.

Visit the Douglas Archives Forum.

 

We try to keep everyone up to date with new entries, via our What's New section on the home page.

We also use the Community Network to keep researchers abreast of developments in the Douglas Archives.

 
 
 


Back to top

The content of this website is a collection of materials gathered from a variety of sources, some of it unedited.

The webmaster does not intend to claim authorship, but gives credit to the originators for their work.

As work progresses, some of the content may be re-written and presented in a unique format, to which we would then be able to claim ownership.

Discussion and contributions from those more knowledgeable is welcome.

Contact Us

Last modified: Saturday, 18 March 2017